A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
NCT ID: NCT03847649
Last Updated: 2025-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
60 participants
INTERVENTIONAL
2020-03-09
2031-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
I238B: The purpose of this study is to allow patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
NCT02879162
Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors
NCT03081923
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
NCT04803201
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
NCT03158064
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT00667615
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
Cohort 2: Standard Risk - Randomize 1:1
* Arm A: Durvalumab plus prednisone
* Arm B: Durvalumab (+/- tremelimumab)
For BR34 pts only: Durvalumab (+/- Tremelimumab)
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: High Risk
Durvalumab
1500 mg IV, 60 min, Day 1 every 4 weeks
Prednisone
0.5mg/kg; PO, Daily cycles 1 \& 2
Cohort 2: Standard Risk - Arm A
Durvalumab
1500 mg IV, 60 min, Day 1 every 4 weeks
Prednisone
10mg, PO, Daily cycles 1 \& 2
Cohort 2: Standard Risk - Arm B
Durvalumab
1500 mg IV, 60 min, Day 1 every 4 weeks
Tremelimumab
Patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Durvalumab
1500 mg IV, 60 min, Day 1 every 4 weeks
Prednisone
0.5mg/kg; PO, Daily cycles 1 \& 2
Prednisone
10mg, PO, Daily cycles 1 \& 2
Tremelimumab
Patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must live within Canada and have received durvalumab alone, or durvalumab in combination with tremelimumab, with or without chemotherapy/targeted therapy. Patients who have received other anti PD-1/PD-L1 agents +/- anti CTLA agents are eligible, providing full details of prior therapy, toxicity and management are available. Consult with CCTG for further details.
* Patients must have previously discontinued immunotherapy due to an irAE.
* Immune-related adverse events must have resolved to ≤ grade 1 or baseline and patient must have completed corticosteroid therapy at least 28 days prior to registration in this current study.
* Complete response, partial response or prolonged stable disease (SD ≥ 8 weeks) to initial immunotherapy. Patients that received prior adjuvant/neoadjuvant/consolidation immunotherapy are eligible providing there has been at least a 6 month treatment free interval prior to enrollment and patient has received at least one standard-of-care chemotherapy regimen in the palliative setting (discuss with CCTG if chemotherapy is not considered standard of care or not indicated or patient refused/not eligible as such patients are eligible).
* Patients must have a life expectancy of at least 12 weeks.
* Tumour material may have already been submitted to CCTG for the initial trial. If an additional formalin fixed paraffin embedded tissue block (from their primary or metastatic tumour) is available from tissue collected after immunotherapy discontinuation, patients must have provided informed consent for the release of the block. All patients must have provided informed consent for correlative studies. If patients from non-CCTG trials or commercial use are eventually enrolled, tumour material is also required if available, preferably from tissue collected after immunotherapy discontinuation.
* Presence of clinically and/or radiologically documented disease. All radiology studies must be performed within 28 days prior to enrollment (within 35 days if negative). Patients ideally should have measurable disease.
* ECOG performance status 0 or 1
* Previous Therapy
* Patients who received other relevant standard cancer therapies since discontinuing immunotherapy remain eligible for inclusion as follows:
* Patients may have received prior cytotoxic chemotherapy following discontinuation of immunotherapy for irAE.
* Patients may have received other prior therapies such as tyrosine kinase inhibitors or other targeted agents, following discontinuation of immunotherapy for irAE.
* Patients may not have received subsequent immune checkpoint inhibitors (anti-PD-(L)1 and anti-CTLA-4) following discontinuation of immunotherapy for irAE. Vaccines and oncolytic viruses are permitted.
* Patients must have recovered from all reversible toxicity related to prior chemotherapy or systemic therapy (unless grade 1, irreversible, or considered by investigator as not clinically significant) and have adequate washout as follows: Longest of one of the following:
* Two weeks;
* 5 half-lives for investigational agents;
* Standard cycle length of standard therapies.
* Prior external beam radiation is permitted provided a minimum of 28 days (4 weeks) have elapsed between the last dose of radiation and date of enrollment. Exceptions may be made for low-dose, non-myelosuppressive radiotherapy after consultation with CCTG. Concurrent radiotherapy is not permitted.
* Previous surgery is permitted provided that a minimum of 28 days (4 weeks) have elapsed between any major surgery and date of enrollment, and that wound healing has occurred.
* Absolute neutrophils ≥ 1.5 x 10\^9/L
* Platelets ≥ 100 x 10\^9/L
* Hemoglobin ≥ 90 g/L
* Bilirubin ≤ 1.5 x ULN (upper limit of normal)
* AST and ALT ≤ 2.5 x ULN - ≤ 5.0 x ULN (if patient has liver metastases)
* Serum creatinine \< 1.25 x ULN or
* Creatinine clearance ≥ 40 mL/min
* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.
* Patients must be accessible for treatment and follow up. Patients registered on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits (for example: 1 ½ hour's driving distance) placed on patients being considered for this trial.
* In accordance with CCTG policy, protocol treatment is to begin within 2 working days of patient enrollment
* Women/men of childbearing potential must have agreed to use a highly effective contraceptive method
* Subjects should not donate blood while participating in this study, or for at least 90 days following the last infusion of durvalumab
* Patients must be currently enrolled and receiving active treatment on a treatment arm containing durvalumab +/- tremelimumab with or without maintenance pemetrexed with no contraindications to continue receiving their current study regimen according to the protocol to which the patient is currently enrolled.
* For BR.34 ONLY: patients who have disease progression (iUPD) on durvalumab may receive one dose of tremelimumab (75 mg) along with their next durvalumab infusion as long as all the following criteria are met:
* Patient is clinically stable
* According to the judgement of the treating physician, the patient had clinical benefit while receiving tremelimumab in the induction phase on BR.34
* ECOG performance status of 0 or 1
* Laboratory values meet the criteria below:
Absolute neutrophils ≥ 1.5 x 10\^9/L Platelets ≥ 100 x 10\^9/L Hemoglobin ≥ 90 g/L Bilirubin ≤ 1.5 x ULN (upper limit of normal)\* AST and ALT ≤ 2.5 x ULN (if liver metastases are present, ≤ 5.0 x ULN) Serum creatinine \< 1.25 x ULN or Creatinine clearance ≥ 45 mL/min
Exclusion Criteria
* History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of enrollment.
* Live attenuated vaccination administered within 30 days prior to enrollment or within 30 days of receiving durvalumab.
* History of hypersensitivity to durvalumab or any excipient.
* Any immune-related adverse event that required biologic agents such as infliximab, or mycophenolate motefil to manage.
* Documented progressive disease (PD) while on initial immunotherapy. Exception: patients who had iUPD but continued on immunotherapy, and did not have documented iCPD within 8 weeks of discontinuing immunotherapy
* Patients who have experienced untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous year or cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects). Patients with a significant cardiac history, even if controlled, should have a LVEF ≥ 50%.
* Concurrent treatment with other investigational drugs or anti-cancer therapy.
* Patients with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol (including corticosteroid administration), or would put the patient at risk. This includes but is not limited to:
* History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or limit compliance with study requirements.
* Active infection requiring systemic therapy; (including any patient known to have active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) or tuberculosis or any infection requiring systemic therapy).
* Active peptic ulcer disease or gastritis.
* Untreated symptomatic brain metastases or brain metastases in whom radiation or surgery is indicated.
* Patients with diabetes mellitus are eligible but must be clinically stable on therapy (if applicable) and investigator and patient should be aware of the potential risk of immune mediated pancreatic toxicity and B cell destruction.
* Pregnant or lactating women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Canadian Cancer Trials Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Ellis
Role: STUDY_CHAIR
Juravinski Cancer Centre at Hamilton Health Sciences Centre, Hamilton, ON Canada
Sara K Taylor
Role: STUDY_CHAIR
BCCA-Cancer Centre for the Southern Interior, Kelowna, BC Canada
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cross Cancer Institute
Edmonton, Alberta, Canada
BCCA - Kelowna
Kelowna, British Columbia, Canada
BCCA - Vancouver
Vancouver, British Columbia, Canada
Regional Health Authority B, Zone 2
Saint John, New Brunswick, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Waterloo Regional Health Network (WRHN)
Kitchener, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
Windsor Regional Cancer Centre
Windsor, Ontario, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ)
Québec, Quebec, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Quincy Chu
Role: primary
Sara Kristina Taylor
Role: primary
Christian Kollmannsberger
Role: primary
Anthony J. Reiman
Role: primary
Peter Ellis
Role: primary
Stacey Hubay
Role: primary
Scott Laurie
Role: primary
Penelope A. Bradbury
Role: primary
Swati Kulkarni
Role: primary
Normand Blais
Role: primary
Andre Blais
Role: primary
Nayyer Iqbal
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I238
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.